| Symbol | CLRB |
|---|---|
| Name | CELLECTAR BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 100 CAMPUS DRIVE, FLORHAM PARK, New Jersey, 07932, United States |
| Telephone | +1 608 441-8120 |
| Fax | — |
| — | |
| Website | https://www.cellectar.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001279704 |
| Description | Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The companys core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. Additional info from NASDAQ: |
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
Read moreCellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
Read moreCellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
Read moreNew Form 10-K/A - Cellectar Biosciences, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001104659-26-053090 <b>Size:</b> 652 KB
Read moreCellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
Read moreCellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
Read moreCellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Read moreCellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Read more(30% Negative) CELLECTAR BIOSCIENCES, INC. (CLRB) Reports Q1 2026 Financial Results
Read moreCellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00960726 | NOV-002 in Myelodysplastic Syndrome (MDS) | Phase2 | Leukemia | Withdrawn | — | — | ClinicalTrials.gov |
| NCT07311993 | Phase 1 Study of CLR 125 in Triple Negative Breast Cancer | Phase1 | Breast Cancer | Recruiting | 2025-12-05 | 2029-07-01 | ClinicalTrials.gov |
| NCT05610891 | Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or R… | Phase1 | High-Grade Glioma | Active_Not_Recruiting | 2023-10-01 | 2026-09-01 | ClinicalTrials.gov |
| NCT04105543 | CLR 131 Combined With Radiation for Head and Neck Cancer | Phase1 | Head and Neck Cancer | Completed | 2019-12-20 | 2024-02-01 | ClinicalTrials.gov |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tum… | Phase1 | Pediatric Solid Tumor | Active_Not_Recruiting | 2019-04-30 | 2027-02-25 | ClinicalTrials.gov |
| NCT02952508 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) Wi… | Phase2 | Waldenstrom Macroglobulinemia | Active_Not_Recruiting | 2017-07-26 | 2027-12-22 | ClinicalTrials.gov |
| NCT02278315 | Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory … | Phase1 | Multiple Myeloma | Completed | 2015-02-01 | 2022-08-10 | ClinicalTrials.gov |
| NCT01778088 | Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma | Phase2 | Glioma | Withdrawn | 2014-05-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01898273 | Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent … | Phase2 | Glioblastoma | Terminated | 2014-02-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01662284 | Study of 124I-NM404 in Advanced Solid Malignancies | — | Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer | Terminated | 2012-07-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01058512 | A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy | Phase2 | Hepatitis C | Completed | 2010-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00925275 | Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanc… | Phase1 | Solid Tumors | Completed | 2009-06-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00347412 | Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer | Phase3 | Non Small Cell Lung Cancer | Completed | 2006-11-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00372983 | Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy | Phase1 | Hepatitis C | Completed | 2006-08-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00345540 | Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant O… | Phase2 | Ovarian Cancer | Completed | 2006-07-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00582283 | NM404 as an Imaging Agent in Patients With NSCLC | Phase1 | Non Small Cell Lung Cancer | Completed | 2004-01-14 | 2014-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| I-131-CLR1404 Injection | Other | Phase PHASE2 | Glioma | WITHDRAWN | NCT01778088 |
| I-124-CLR1404 | Other | Phase PHASE2 | Glioblastoma | TERMINATED | NCT01898273 |
| 124I-NM404 | Other | Preclinical | Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer | TERMINATED | NCT01662284 |
| NOV-205 | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01058512 |
| dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02278315 |
| I-131-CLR1404 | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02278315 |
| CLR 131 | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT04105543 |
| CLR 131 | Other | Phase PHASE1 | High-Grade Glioma | ACTIVE_NOT_RECRUITING | NCT05610891 |
| CLR 131 | Other | Phase PHASE1 | Pediatric Solid Tumor | ACTIVE_NOT_RECRUITING | NCT03478462 |
| Iopofosine I 131 fractionated dose | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT02952508 |
| Iopofosine I 131 multiple dose | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT02952508 |
| Iopofosine I 131 single dose | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT02952508 |
| CLR 125 | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT07311993 |
| Iopofosine I 131 | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT07311993 |
| CLR 125 | DRUG | Phase PHASE1 | Breast Cancer | RECRUITING | NCT07311993 |
| Iopofosine I 131 | DRUG | Phase PHASE1 | Breast Cancer | RECRUITING | NCT07311993 |
| CLR 131 | DRUG | Phase PHASE1 | High-Grade Glioma | ACTIVE_NOT_RECRUITING | NCT05610891 |
| Iopofosine I 131 fractionated dose | DRUG | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT02952508 |
| Iopofosine I 131 multiple dose | DRUG | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT02952508 |
| Iopofosine I 131 single dose | DRUG | Phase PHASE2 | Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT02952508 |
| dexamethasone | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02278315 |
| I-124-CLR1404 | DRUG | Phase PHASE2 | Glioblastoma | TERMINATED | NCT01898273 |
| I-131-CLR1404 Injection | DRUG | Phase PHASE2 | Glioma | WITHDRAWN | NCT01778088 |
| 124I-NM404 | DRUG | Preclinical | Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer | TERMINATED | NCT01662284 |
| I-131-CLR1404 | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02278315 |
| I124-NM404 | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT00582283 |
| NOV-205 | DRUG | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01058512 |
| Paclitaxel | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | COMPLETED | NCT00347412 |
| Carboplatin | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | COMPLETED | NCT00347412 |
| NOV-002 | DRUG | Phase PHASE2 | Leukemia | WITHDRAWN | NCT00960726 |